7 hrs ago
Puma Biotechnology Announces Positive Top Line Results From Phase III ...
Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced top line results from the Phase III clinical trial of Puma's investigational drug PB272 for the extended adjuvant treatment of breast cancer .
Mon Jul 21, 2014
Waistlines of U.S. kids seem to be holding steady
New mothers who return to work full-time are less likely to stick with their breast-feeding goals than those who go back to work part-time, a new study finds.
Thu Jul 17, 2014
Scientists create 'biological pacemaker' in pig hearts
Researchers say they've found a way to transform ordinary pig heart muscle cells into a "biological pacemaker," a feat that might one day lead to the replacement of electronic pacemakers in humans.
Tue Jul 15, 2014
British Journal of Cancer
HER2-positive advanced breast cancer: optimizing patient outcomes and ...
Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, 160 East 34th Street, New York, NY 10016, USA Effective targeting of the human epidermal growth factor receptor 2 has changed the natural history of HER2 overexpressing metastatic breast cancer.
Sun Jul 06, 2014
Medical News Today
Potential new treatment for aggressive breast cancer
Researchers have discovered a "viable" new target for the treatment of a particularly aggressive form of breast cancer.
Fri Jul 04, 2014
Significant discovery could tackle spread of breast cancer
For the first time, researchers from Queen Mary University of London have revealed the molecule I vI26 plays a fundamental role in helping breast cancer cells to grow and spread.
Wed Jul 02, 2014
Recent Findings from National Cancer Institute Advance Knowledge in...
To elucidate mechanisms associated with this therapy, targeted ?-particle radiation therapeutic Pb-TCMC-trastuzumab together with paclitaxel was investigated for the treatment of disseminated peritoneal cancers."
Tue Jul 01, 2014
Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax
Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the notice of allowance of a U.S. Patent for NeuVax covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu ... (more)